PT  - JOURNAL ARTICLE
AU  - Matthew T. Maurano
AU  - Sitharam Ramaswami
AU  - Gael Westby
AU  - Paul Zappile
AU  - Dacia Dimartino
AU  - Guomiao Shen
AU  - Xiaojun Feng
AU  - André M. Ribeiro-dos-Santos
AU  - Nicholas A. Vulpescu
AU  - Margaret Black
AU  - Megan S. Hogan
AU  - Christian Marier
AU  - Peter Meyn
AU  - Yutong Zhang
AU  - John Cadley
AU  - Raquel Ordoñez
AU  - Raven Luther
AU  - Emily Huang
AU  - Emily Guzman
AU  - Antonio Serrano
AU  - Brendan Belovarac
AU  - Tatyana Gindin
AU  - Andrew Lytle
AU  - Jared Pinnell
AU  - Theodore Vougiouklakis
AU  - Ludovic Boytard
AU  - John Chen
AU  - Lawrence H. Lin
AU  - Amy Rapkiewicz
AU  - Vanessa Raabe
AU  - Marie I. Samanovic-Golden
AU  - George Jour
AU  - Iman Osman
AU  - Maria Aguero-Rosenfeld
AU  - Mark J. Mulligan
AU  - Paolo Cotzia
AU  - Matija Snuderl
AU  - Adriana Heguy
TI  - Sequencing identifies multiple, early introductions of SARS-CoV2 to New York City Region
AID  - 10.1101/2020.04.15.20064931
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.15.20064931
4099  - http://medrxiv.org/content/early/2020/04/23/2020.04.15.20064931.short
4100  - http://medrxiv.org/content/early/2020/04/23/2020.04.15.20064931.full
AB  - Effective public response to a pandemic relies upon accurate measurement of the extent and dynamics of an outbreak. Viral genome sequencing has emerged as a powerful approach to link seemingly unrelated cases, and large-scale sequencing surveillance can inform on critical epidemiological parameters. Here, we report the analysis of 236 SARS-CoV2 sequences from cases in the New York City metropolitan area during the initial stages of the 2020 COVID-19 outbreak. The majority of cases throughout the region had no recent travel history or known exposure, and genetically linked cases were spread throughout the region. Comparison to global viral sequences showed that the majority were most related to cases from Europe. Our data are consistent with numerous seed transmissions from multiple sources and a prolonged period of unrecognized community spreading. This work highlights the complementary role of real-time genomic surveillance in addition to traditional epidemiological indicators.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially funded by NIH grants P30CA016087 (NYU Langone Genome Technology Center), UM1AI148574 (M.J.M), and R35GM119703 to (M.T.M.). This work was partially supported by the NYULH Office for Science and Research.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequences have been deposited into the GISAID repository immediately upon QC and can be visualized at http://nextstrain.org/ncov . http://www.mauranolab.org/SARSCoV2.html